Amerikanische Gesellschaft für Hirudotherapie

Chronic Postsurgical Pain Syndrome (Investigational Adjunct)

Investigational adjunct for chronic postsurgical pain after surgical site healed; multimodal pain management including pharmacotherapy, physical therapy, and (for neuropathic features) interventional pain procedures remain evidence-based.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for chronic postsurgical pain. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic postsurgical pain syndrome is investigational.
Welche Evidenz existiert?
Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based therapy for chronic postsurgical pain (pain persisting >3 months after surgery): multimodal pain management including gabapentin/pregabalin, tricyclic antidepressants or SNRIs (duloxetine), topical lidocaine or capsaicin for neuropathic component, physical therapy, cognitive-behavioral therapy, and interventional procedures (nerve blocks, neuromodulation) for refractory cases.
Hauptrisiken
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over surgical scar areas
  • Local skin infection or, rarely, Aeromonas infection near a surgical wound
  • Allergic reaction to leech saliva (uncommon)
  • Worsening of neuropathic pain after the procedure
  • Risk if leech placed too close to surgical mesh or hardware
  • Permanent small scars added to surgical scar
  • Delay of multimodal pain management or pain psychology
Wer dies nicht in Betracht ziehen sollte
  • Patients within 12 weeks of surgery (wound-healing concerns)
  • Patients with active surgical-site infection
  • Patients with prosthetic hardware or mesh at the proposed site (infection risk)
  • Patients with opioid use disorder (risk substitution rather than addressing root)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not tried multimodal pharmacologic and physical therapy management
Was Sie Ihren Kliniker fragen sollten
  • Have I been evaluated by a pain management specialist?
  • Have I tried gabapentin, pregabalin, duloxetine, or amitriptyline for neuropathic pain?
  • Have I had pain psychology or cognitive-behavioral therapy?
  • Am I a candidate for nerve block, peripheral nerve stimulation, or neuromodulation?
  • What evidence specifically supports leech therapy for postsurgical pain?
  • Is leech application safe near my surgical mesh or hardware?
  • What is the cost and is it covered by insurance? (typically not covered)
Wann dringende medizinische Versorgung suchen
  • Spreading redness, warmth, pus, or red streaks near the surgical scar (possible deep infection)
  • Sudden severe pain, swelling, or fever (possible hardware or mesh infection)
  • New numbness, weakness, or loss of function
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • This is NOT FDA-cleared for chronic postsurgical pain syndrome.
  • Anecdotal reports do NOT establish efficacy versus multimodal pharmacologic and physical therapy.
  • It does NOT address neuropathic pain mechanisms that drive most chronic postsurgical pain.
  • It does NOT substitute for pain psychology, cognitive-behavioral therapy, or interventional procedures.
  • It does NOT mean leech application is safe near surgical hardware, mesh, or prosthetics.

Clinical Profile

Category
other
ICD-10
G89.21, G89.28, G89.4
Safety tier
medium

Evidence Summary

Chronic postsurgical pain (CPSP) is pain persisting beyond 3 months after surgery, not attributable to other causes. Common in thoracotomy, mastectomy, inguinal hernia repair, amputation, and cesarean section. Evidence-based multimodal management: pharmacotherapy with gabapentinoids and serotonin-norepinephrine reuptake inhibitors for neuropathic features, NSAIDs for inflammatory features, topical lidocaine or capsaicin, physical therapy with scar mobilization, and (for refractory cases) interventional pain procedures including peripheral nerve blocks, neuroma injection, or spinal cord stimulation. No published controlled trials of hirudotherapy exist for CPSP. Anecdotal periscar application is described in central European practice, with rationale of scar pliability and local hyperemia. Direct placement on a healed scar requires caution if the wound is recent (<6 months) or if the scar is keloid-prone.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Recent surgery (<6 months) or unhealed wound
  • Active surgical site infection or seroma
  • Suspected suture or implant pathology
  • Underlying tumor recurrence in the surgical bed (oncology workup first)
  • Implanted device near placement site (pacemaker, port, ICD)

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Chronic Postsurgical Pain Syndrome (Investigational Adjunct) — Hirudotherapy Evidence | ASH